These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 18430617

  • 1. Recent advances in the management of Crohn's disease.
    Caprilli R, Angelucci E, Clemente V.
    Dig Liver Dis; 2008 Sep; 40(9):709-16. PubMed ID: 18430617
    [Abstract] [Full Text] [Related]

  • 2. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
    Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
    [Abstract] [Full Text] [Related]

  • 3. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ, PRECISE 2 Study Investigators.
    N Engl J Med; 2007 Jul 19; 357(3):239-50. PubMed ID: 17634459
    [Abstract] [Full Text] [Related]

  • 4. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease.
    Shao LM, Chen MY, Cai JT.
    Aliment Pharmacol Ther; 2009 Mar 15; 29(6):605-14. PubMed ID: 19183161
    [Abstract] [Full Text] [Related]

  • 5. Certolizumab pegol for the management of Crohn's disease in adults.
    Rivkin A.
    Clin Ther; 2009 Jun 15; 31(6):1158-76. PubMed ID: 19695385
    [Abstract] [Full Text] [Related]

  • 6. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
    Peyrin-Biroulet L.
    Minerva Gastroenterol Dietol; 2010 Jun 15; 56(2):233-43. PubMed ID: 20485259
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
    D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S.
    Am J Gastroenterol; 2011 Feb 15; 106(2):199-212; quiz 213. PubMed ID: 21045814
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease.
    Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ.
    Aliment Pharmacol Ther; 2010 Aug 15; 32(3):384-93. PubMed ID: 20491747
    [Abstract] [Full Text] [Related]

  • 12. How to manage difficult Crohn's disease: optimum delivery of anti-TNFs.
    Krygier DS, Ko HH, Bressler B.
    Expert Rev Gastroenterol Hepatol; 2009 Aug 15; 3(4):407-15. PubMed ID: 19673627
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Anti-TNF-alpha treatment strategies: results and clinical perspectives.
    D'Haens G.
    Gastroenterol Clin Biol; 2009 Jun 15; 33 Suppl 3():S209-16. PubMed ID: 20117344
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Early treatment in Crohn's disease: do we have enough evidence to reverse the therapeutic pyramid?
    Fascì Spurio F, Aratari A, Margagnoni G, Doddato MT, Papi C.
    J Gastrointestin Liver Dis; 2012 Mar 15; 21(1):67-73. PubMed ID: 22457862
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
    Seiderer J, Brand S, Dambacher J, Pfennig S, Jürgens M, Göke B, Ochsenkühn T.
    Aliment Pharmacol Ther; 2007 Apr 01; 25(7):787-96. PubMed ID: 17373917
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.